Pfizer Abandons Twice-Daily Weight Loss Pill After Trial Results Pfizer announced on Friday that it would discontinue developing the twice-daily version of its experimental weight loss pill. The decision followed a mid-stage clinical study that showed obese patients taking the drug experienced weight loss but grappled with intolerable side effects. This move has set back …
Eli Lilly surpasses expectations but lowers profit outlook Eli Lilly reported better-than-expected financial results for the third quarter, driven by strong demand for its diabetes drug Mounjaro. The pharmaceutical company reported earnings of $0.10 per share, surpassing estimates of a loss of $0.13 per share. Revenue also exceeded expectations, coming in at $9.50 billion compared …
Here’s our Club Mailbag email — so you can send your questions directly to Jim Cramer and his team of analysts. Please note that we are unable to provide personal investing advice. However, we would be happy to address more general questions about the investment process, stocks in the portfolio, or related industries. This week’s …
During the October Monthly Meeting, we had the opportunity to address questions from our Investing Club members. Below, you’ll find the answers provided by Jim Cramer and portfolio director Jeff Marks, revised for clarity and optimized for SEO. Let’s dive in! Question 1: Why do rising interest rates have a negative impact on technology stocks? …
Jim Cramer on Squawk on the Street, June 30, 2022. Virginia Sherwood | CNBC In a recent episode of “Squawk on the Street,” Jim Cramer from CNBC recommended that investors pay attention to Vertex Pharmaceuticals (VRTX). This biotechnology company is currently developing a non-opioid drug to treat acute pain. Cramer stated, “The biggest challenge in …
McCormick spices are displayed on a shelf at a supermarket in San Anselmo, California, on March 28, 2023. Justin Sullivan | Getty Images News | Getty Images Explore the latest market movers. Warby Parker saw a 3.4% increase in its stock price after Evercore ISI upgraded the shares to outperform. The firm predicts that 2024 …
Co-CEOs, Neil Blumenthal & Dave Gilboa of Warby Parker at the NYSE, September 29, 2021. Source: NYSE Discover the companies capturing attention prior to the opening bell. Warby Parker — Warby Parker experienced a 4% surge after receiving an outperform rating upgrade from Evercore ISI. The upgrade predicted a potential rally of over 50% in …
Aykut Karahan | Istock | Getty Images Shares of Structure Therapeutics surged more than 30% on Friday after the successful Phase 1b trial of their experimental obesity pill. In a small early-stage trial, the once-daily drug helped overweight or obese participants lose an average of 10 pounds after four weeks of treatment, as announced in …
A pharmacist displays boxes of Ozempic, a semaglutide injection drug used for treating type 2 diabetes made by Novo Nordisk, at Rock Canyon Pharmacy in Provo, Utah, U.S. March 29, 2023. George Frey | Reuters According to a new analysis released Wednesday by Trilliant Health, U.S. health care providers have written over nine million prescriptions …
There’s Eli Lilly (LLY), and then there’s everybody else. That’s a simple way to describe the performance of the Club’s health-care holdings so far this year, in what’s been a challenging period for the industry overall. Of the 11 market sectors year to date, health care is the fourth worth-worst performer, falling 4%, followed by …